State of the 340B Program Key Statistics

This report presents key statistics and forecasts regarding the 340B program, a federal program that allows eligible healthcare organizations to purchase drugs at significantly reduced prices. The report outlines a notable increase in 340B-priced drug purchases, which grew by 22.1 percent annually over the last five years, reaching $68 billion in 2023. Additionally, it documents a 123% rise in contract pharmacy arrangements within the same period. The analysis also forecasts that by 2027, one in four 340B drug purchases will be dispensed by contract pharmacies. Furthermore, it highlights that the average discount off the list price for drugs purchased at the 340B price is projected to exceed that of federal drug programs by 2027. These statistics indicate a significant expansion of the 340B program, influencing both gross and net sales figures for the coming years.